Dow Up0.82% Nasdaq Up0.70%

Halozyme Therapeutics, Inc. (HALO)

10.07 Up 0.37(3.81%) 4:00PM EDT
|After Hours : 10.07 Up 0.00 (0.02%) 4:52PM EDT
ProfileGet Profile for:
Halozyme Therapeutics, Inc.
11388 Sorrento Valley Road
San Diego, CA 92121
United States - Map
Phone: 858-794-8889
Fax: 858-704-8311

Index Membership:N/A
Full Time Employees:216

Business Summary 

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. The company is also developing PEGylated recombinant human hyaluronidase (PEGPH20) for the treatment of metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and other cancers in combination with various cancer therapies. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd., Hoffmann-La Roche, Inc., Baxalta US Inc., Baxalta GmbH, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., and Eli Lilly and Company. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Halozyme Therapeutics, Inc.

Corporate Governance 
Halozyme Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 6. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 10; Compensation: 2.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., 53
Chief Exec. Officer, Pres and Director
Ms. Laurie D. Stelzer , 48
Chief Financial Officer and Sr. VP
Mr. Harry J. Leonhardt Esq., 59
Chief Compliance Officer, Sr. VP, Gen. Counsel and Corp. Sec.
Dr. Athena Countouriotis M.D., 44
Chief Medical Officer and Sr. VP
Dr. Michael J. LaBarre Ph.D., 52
Chief Scientific Officer and VP
Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders